Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
August 2, 2022
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
Abstract: The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and “Ab” is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
Type:
Grant
Filed:
September 2, 2021
Date of Patent:
August 2, 2022
Assignees:
Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
Inventors:
Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
Abstract: The present invention describes methods of monitoring the efficacy of a pulmonary fibrosis, such as idiopathic pulmonary, fibrosis (IPF), treatment. Also described are methods of predicting the progression of IPF. These methods are based, at least in part, on the presence and/or level of CCR10-positive cells.
Abstract: The present invention refers to a method for the production of activated CD3-CD56+ NK cells, activated CD3-CD56 NK+ cells obtainable with the method, their use, in particular for the treatment of a tumor, preferably a hepatocellular carcinoma (HCC), for use in the treatment and/or prevention of an HCV infection, for use in the treatment and/or prevention of a post-liver transplant HCV reinfection, or for use for prevention of a post-liver transplant HCC recurrence. The invention also concerns pharmaceutical compositions including the activated CD3-CD56+ NK cells.
Type:
Grant
Filed:
November 29, 2017
Date of Patent:
July 19, 2022
Assignees:
FONDAZIONE RI.MED, ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE . ISMETT
Abstract: The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
June 28, 2022
Assignee:
ProKidney
Inventors:
Joydeep Basu, Kelly Guthrie, Dominic Justewicz, Teresa Burnette, Andrew Bruce, Russell W. Kelley, John W. Ludlow
Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
Type:
Grant
Filed:
August 4, 2021
Date of Patent:
May 24, 2022
Inventors:
Nicholas D. Huntington, Sandra E. Nicholson
Abstract: The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.
Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
Type:
Grant
Filed:
November 2, 2018
Date of Patent:
May 17, 2022
Assignee:
MOLECULAR PARTNERS AG
Inventors:
Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
Abstract: Provided in the present invention are uses of a compound as represented by formula I in preparing a stem cell apoptosis antagonist. Also provided are uses of the compound as represented by formula I in preparing a medicament for preventing or treating cell apoptosis-related diseases, and a culturing method employing the compound as represented by formula I for stem cell culturing. The compound as represented by formula I is (I).
Type:
Grant
Filed:
May 17, 2017
Date of Patent:
May 10, 2022
Assignee:
BEIJING NORMAL UNIVERSITY
Inventors:
Mei Han, Jinhua Wen, Ying Sun, Huajun Li
Abstract: There is disclosed compositions and methods relating to or derived from anti-WISP1 antibodies. More specifically, there is disclosed fully human antibodies that bind WISP1, WISP1-binding fragments and derivatives of such antibodies, and WISP1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having WISP1 related disorders or conditions. There is also disclosed a method for treating or preventing various cancers or inflammatory diseases and various diseases of the heart, bone/joints or lung.
Abstract: The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
Abstract: Disclosed herein are methods and compositions for stimulating angiogenesis, using cells descended from marrow adherent stromal cells that have been transfected with sequences encoding a Notch intracellular domain. Applications of these methods and compositions include treatment of ischemic disorders such as stroke.
Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
April 12, 2022
Assignee:
Xencor, Inc.
Inventors:
Gregory Moore, Rumana Rashid, John Desjarlais
Abstract: The present invention relates to alternatively activated macrophages (AAMs) for use in the treatment of liver injury and methods of treating and preventing liver injury using AAMs.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
March 29, 2022
Assignee:
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
Inventors:
Stuart Forbes, Philip Starkey Lewis, Lesley Forrester
Abstract: Provided herein are, inter alia, methods, compositions, and kits for producing adipocyte populations such as beige adipocyte populations. Also included are methods and compositions for increasing the level of adipocyte populations (e.g., beige adipocyte populations) in a subject, as well as methods and compositions for treating subjects who are overweight, obese, or who have diabetes.
Abstract: An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
Type:
Grant
Filed:
July 19, 2021
Date of Patent:
March 22, 2022
Assignee:
The Walter and Eliza Hall Institute of Medical Research
Inventors:
Nicholas D. Huntington, Sandra E. Nicholson
Abstract: The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNF?), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
Type:
Grant
Filed:
April 12, 2019
Date of Patent:
March 15, 2022
Assignee:
PHILOGEN S.P.A.
Inventors:
Roberto De Luca, Francesca Pretto, Sarah Wulhfard
Abstract: Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
February 15, 2022
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Tzuhua Dennis Lin, Stuart B. Goodman, Sai-Wen Tang, Everett Hurteau Meyer, Magdiel Pérez Cruz